News

Podcast

Taletrectinib Takes Aim: A New Chapter in ROS1-Positive NSCLC

Author(s):

Alexandra Gerlach, Associate Editor,Kevin Chen, PharmD

Kevin Chen, PharmD, MS, BCOP, CPP; and Amanda Cass, PharmD, BCPS, BCOP, share key insights about ROS1, non-small cell lung cancer, and the newly approved drug taletrectinib.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Monoclonal antibodies are used to treat lung cancer. They are created in a lab and designed to target specific proteins on cancer cells, stopping them from growing and dividing.
Gene therapy in lung cancer (LC) - isometric view 3d illustration
Related Content
Image credit: Halfpoint | stock.adobe.com
September 12th 2025

Study: How Stress and Diet Disrupt a Brain Circuit to Increase Diabetes Risk

Kennedy Ferruggia, Assistant Editor
ESC 2023 Highlights: Insights on ALONE-AF and AQUATIC Trials
September 12th 2025

ESC 2023 Highlights: Insights on ALONE-AF and AQUATIC Trials

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP Aislinn Antrim, Managing Editor
Optimizing Parenteral Nutrition: A Pharmacist-Led Quality Improvement Initiative
September 12th 2025

Optimizing Parenteral Nutrition: A Pharmacist-Led Quality Improvement Initiative

Emilia Welch, PharmD, MBA
Pharmacy focus oncology Edition, radon and lung cancer
September 12th 2025

A Silent Killer: Unmasking Radon’s Link to Lung Cancer

Alexandra Gerlach, Associate Editor
INLEXZO™ Image to Scale - Image credit: Johnson & Johnson
September 12th 2025

Gemcitabine Intravesical System Receives FDA Approval for Non–Muscle Invasive Bladder Cancer

Kennedy Ferruggia, Assistant Editor
Woman with PCOS -- Image credit: SewcreamStudio | stock.adobe.com
September 12th 2025

Study: Women With PCOS at Increased Risk of Acute Myocardial Infarction and Ischemic Stroke

Gillian McGovern, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.